ntravenous immune globulin
(IVIG) products have several
Food and Drug Administration–
approved indications, including use
in primary humoral immunodefi
-
ciency, chronic inflammatory de
-
myelinating polyneuropathy, B-cell
chronic lymphocytic leukemia, mul
-
tifocal motor neuropathy, Kawasaki
syndrome, and chronic idiopathic
thrombocytopenic purpura.
1,2
IVIG
has been studied for the treatment
of a variety of bacterial and viral
infectious diseases that do not re
-
spond to conventional therapy.
3
Specifically, IVIG has been associ
-
ated with improved outcomes in
parvovirus B19 infection, West Nile
Virus–induced encephalitis, respira
-
tory syncytial virus infection, and
Clostridium difficile
infection (CDI)
and can be used as an adjunct in
the treatment of streptococcal toxic
shock syndrome